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BACKGROUND: Medicare Part D prescription drug
plans (PDPs) implemented in January 2006 are de-
signed to improve beneficiaries’ access to pharmaceu-
ticals and use market competition to yield affordable
drug costs. Variations in estimated PDP costs for
beneficiaries living in different states have not previ-
ously been characterized.
OBJECTIVE: To describe variations in the estimated
costs of PDPs (plan premium, copays, and coinsurance)
within and across states.
DESIGN: To estimate PDP costs based on 4 actual
patient cases that exemplify common conditions and
prescription drug combinations for Medicare beneficia-
ries, we used the online tool provided by the Centers for
Medicare and Medicaid Services.
MEASUREMENTS: Principal study outcomes included
(a) variation across states in the estimated annual cost
of the lowest-cost PDP for each case and (b) variation in
the estimated affordability of the lowest-cost PDPs
across states, based on cost-of-living-adjusted median
income for zero-earner households.
RESULTS: For all 4 patient cases, we found substan-
tive within-state and between-state differences in the
estimated costs of Medicare PDPs incurred by benefi-
ciaries. The estimated annual costs to beneficiaries of
the lowest-cost PDPs varied across states by as much as
$320 for medications in the least expensive scenario,
and by as much as $13,000 for the most expensive
scenario. On average across states, a beneficiary with
cost-of-living-adjusted median income would expect to
spend 3%–28% of annual income to pay for medications
in the lowest-cost PDPs in the 4 patient cases. The
affordability of the lowest-cost plans varied across
states, and for 2 of the 4 cases the lowest-cost PDP
estimates were negatively correlated with cost-of-living-
adjusted median income.
CONCLUSIONS: Substantive differences in estimated
PDP costs are evident across states for patients with
common Medicare conditions. Importantly, the lowest-
cost plans were not proportionally affordable with
respect to state-specific cost-of-living-adjusted median
income. Refinement of the Medicare drug program may
be needed to improve national balance in PDP afford-
ability for beneficiaries living in different states.
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INTRODUCTION
The Medicare Prescription Drug Improvement and Moderniza-
tion Act (MMA) of 2003 guaranteed a drug benefit in the form
of prescription drug plans (PDPs) available to all program
beneficiaries as of January 1, 2006.1 The legislation addressed
a major problem in the pre-MMA era, namely that 9 out of 10
Medicare beneficiaries take prescription medications but more
than one-quarter had no coverage to help them afford the costs
of their medications, as well as those of necessities such as
food or heat.2–6
Through Medicare PDPs, program beneficiaries purchase
their prescription drugs through cost-sharing arrangements
that, under the standard benefit structure described in the
MMA, vary with the beneficiary’s increasing annual out-of-
pocket medication expenses.1 A central tenet of the MMA is
that market competition among PDPs will yield affordable
prescription drug coverage for Medicare beneficiaries.7 Accord-
ing to the Centers for Medicare and Medicaid Services (CMS),
there is some evidence already that market pressures have
brought the average PDP premium below predicted levels.8,9
Most analyses of PDPs have yielded aggregate national
predictions8,10,11 and have not explored possible state-to-state
differences in PDP costs for beneficiaries that may be market-
related. Between-state differences are likely, given known state
and regional differences in health care utilization and costs for
Medicare beneficiaries.12–14 Only one prior study of which we
are aware has examined PDP costs across states,15 but only
analyzed 5 states and did not consider whether known
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differences in PDP formularies and tiered pricing16 would lead
to cost variability among PDPs.
Although cost may not be the only factor that beneficiaries
consider in selecting a PDP, between-state variation in the
costs of PDPs for patients with identical medication needs has
potential clinical and policy implications. Patients with less
affordable plans may be more likely to forgo their medica-
tions2–6 and may incur greater health risks for themselves and
higher direct medical costs for the Medicare program. More-
over, if between-state differences in plan affordability for
otherwise identical medications are perceived as inequitable
within a federally administered program, public and legislative
support for the MMA as currently structured may decline.
With these implications in mind, we examined the estimated
costs of PDPs across states in 4 patient case scenarios that
exemplify common medical circumstances for Medicare bene-
ficiaries. Rather than develop our own model of such costs, we
used an online tool provided by the CMS that was designed to
help beneficiaries determine differences in the expected costs
of their medications under different PDPs available in their
states of residence.
Figure 1. Patient case scenario descriptions and medication lists.
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METHODS
Data Sources
We obtained expected PDP costs from the Medicare Part D
Prescription Drug Plan online comparison tool provided by
CMS (https://www.medicare.gov/MPDPF/Public/Include/
DataSection/Questions/Questions.asp). This tool helps bene-
ficiaries identify the PDP licensed in their zip code of residence
that will have the lowest estimated annual cost, given their
anticipated medications. PDP availability is specific to 34 CMS
regions, which in many instances map to individual states but
in some cases map to more than one state (e.g., North Dakota
and South Dakota are included together, and have the same
PDPs available). For each of 4 patient case scenarios, we
entered information about the prescription medications as
part of a “general plan search,” through which the tool provided
a listing of available PDPs in each state and the District of
Columbia (hereafter referred to as the “51 states”), along with
the estimated annual cost to the Medicare beneficiary for each
available PDP based upon the selected medications.
Case Scenarios
For the 4 patient case scenarios (Fig. 1), we chose actual
patients of the authors (MMD and LKH) with conditions most
common among community-dwelling Medicare beneficiaries
(hypertension, arthritis, heart disease, diabetes, and osteopo-
rosis), and who are also typical in having two or more chronic
conditions.17 We used actual lists of prescription medications
from these patients; generic substitution was assumed, when
possible. We also intentionally used a pair of scenarios (cases 1
and 2) that would illustrate the cost implications of PDP
selection for a patient with worsening severity of disease
(diabetes) within a single plan year to examine the implications
of needing to make changes in medications that could
potentially be anticipated by patients and their physicians.
Data Analysis
For each of the patient cases in each state, using the Medicare
Part D plan comparison tool we identified the estimated
annual cost to a beneficiary of the lowest- and highest-cost
PDPs available in state, along with the names of these lowest-
and highest-cost PDPs. All data regarding estimated costs of
PDPs were gathered in December 2005, at a time of peak
interest in Part D plans immediately prior to implementation of
the new program. Of note, the cost calculated by the online tool
is the estimated annual total cost to the beneficiary for the
specified medications, including the PDP premium, copays,
and coinsurance amounts.
From this information, we generated 2 primary outcomes of
interest: (a) variation across states in the estimated annual
cost of the lowest-cost PDP for each patient case and (b)
variation in the affordability of the lowest-cost PDPs across
states for each patient case. Affordability was defined as the
estimated cost of the lowest-cost PDP, divided by the median
income for zero-wage-earner households in each state18 ad-
justed for state-specific cost-of-living.19 We refer to this denom-
inator as the cost-of-living-adjusted median income (COLA-MI).
We examined the correlation of COLA-MI with PDP costs using
pairwise Pearson correlation statistics. As an additional sec-
ondary outcome of interest, we examined the difference between
the estimated costs of the lowest- and highest-cost PDPs for
each patient case within each state, as a measure of financial
risk to Medicare beneficiaries.
Table 1. Estimated Annual Cost of Prescription Drug Plans for






















AL A 912 1,270 60
AK B 1,028 1,726 176
AZ A 790 1,553 −62
AR A 862 1,423 10
CA A 790 1,532 −62
CO A 824 1,731 −28
CT A 831 1,408 −21
DE A 797 1,447 −55
DC A 806 1,441 −46
FL A 813 3,867 −39
GA A 953 1,533 101
HI B 992 1,435 140
ID A 804 1,586 −48
IL A 890 1,421 38
IN A 868 1,372 16
IA A 760 1,607 −92
KS A 842 1,448 −10
KY A 865 1,375 13
LA A 926 1,298 74
ME B 1,042 1,233 190
MD A 806 1,441 −46
MA A 831 1,408 −21
MI A 903 1,304 51
MN A 751 1,616 −101
MS A 868 1,418 16
MO A 870 1,424 18
MT A 756 1,611 −96
NE A 751 1,616 −101
NV C 990 1,355 138
NH B 1,042 1,232 190
NJ A 796 1,412 −56
NM A 856 1,550 4
NY A 719 1,513 −133
NC A 934 1,329 82
ND A 756 1,611 −96
OH A 894 1,329 42
OK A 854 287 2
OR A 826 1,743 −26
PA A 860 1,350 8
RI A 826 1,413 −26
SC A 937 1,570 85
SD A 760 1,607 −92
TN A 889 1,293 37
TX A 844 1,449 −8
UT A 783 1,607 −69
VT A 826 1,413 −26
VA A 848 1,419 −4
WA A 826 1,743 −26
WV A 847 1,363 −5
WI A 866 1,471 14
WY A 760 1,607 −92
US Mean 852 1,494
*Plan name legend: A = Humana Prescription Drug Plans Standard; B =
Community Care Rx Basic; C = First Health Premier.
†Lowest-cost plan in each state−mean lowest-cost plan for US overall.
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RESULTS
For all 4 patient cases, we found substantive differences in the
estimated costs and affordability of Medicare PDPs for benefi-
ciaries, based on their states of residence.
Patient Case 1: Diabetes (Oral Agent),
Hypertension, Hyperlipidemia, and Depression
The mean estimated cost of the lowest-cost PDP for this patient
across all states was $852 (Table 1). The estimated cost of the
lowest-cost PDP ranged among states from $133 less than the
US mean (New York) to $190 more than the US mean (Maine,
New Hampshire). In all but 5 states, the lowest-cost PDP was
the same plan (coded in Table 1 as Plan “A”). Of note, plans
with the same name operating in different states had estimated
annual costs that fell on both sides of the national mean (e.g.,
Plan A in Michigan and Minnesota).
On average, within each state the highest-cost PDPs were
estimated to be almost $1,500 more expensive than the lowest-
cost PDPs (identities and estimated annual costs of the highest-
cost PDPs for all 4 cases are available from the corresponding
author upon request).
Patient Case 2: Diabetes (Oral Agent + Insulin),
Hypertension, Hyperlipidemia, and Depression
For this patient, the mean estimated annual cost for the
lowest-cost PDP across all states was $1,878 (online Table A
Supplementary Material in Appendix). Estimated costs of the
least expensive PDPs ranged around this US mean from $379
less (New York) to $190 more (North Carolina).
In only 3 states did the lowest-cost plan change from patient
1 to patient 2. In other words, if the patient in case 1 had
needed to add insulin in the middle of a plan year, she/he
would still have had the optimal plan from the perspective of
her/his estimated costs in 48 of 51 states (online Table A
Supplementary Material in Appendix). The highest-cost PDPs
for this case were more than $1,700 more expensive than the
lowest-cost PDPs in each state, on average.
Patient Case 3: Ischemic Heart Disease,
Cardiomyopathy, and Hyperlipidemia
For this patient, the mean estimated annual cost for the
lowest-cost PDP was $2,326, and the states’ lowest-cost PDPs
varied around this mean from $254 less (Iowa, Minnesota,
Montana, Nebraska, North Dakota, South Dakota, Wyoming)
to $822 more (Hawaii) (online Table B Supplementary Material
in Appendix). None of the plans that were lowest-cost for cases
1 and 2 were also lowest-cost for case 3. However, similar to
the dominant plan pattern, we observed for cases 1 and 2, for
case 3 in all but 7 states the lowest-cost PDP had the same
name (Plan “O”). On average, the highest-cost PDPs for this
patient were more than $1,900 more expensive than the
lowest-cost PDPs in each state.
Table 2. Estimated Annual Cost of Prescription Drug Plans for
Patient Case 4 with Osteoporosis, Hypertension,




















AL V 4,538 13,867 −3,608
AK B 17,180 698 9,034
AZ V 4,734 18,226 −3,412
AR O 16,800 6,384 8,654
CA V 4,460 13,406 −3,686
CO O 16,748 1,186 8,602
CT V 4,768 18,195 −3,378
DE V 4,774 19,165 −3,372
DC V 4,856 19,083 −3,290
FL O 16,814 2,564 8,668
GA V 4,516 13,484 −3,630
HI V 4,457 13,523 −3,689
ID V 4,475 13,471 −3,671
IL O 16,827 1,124 8,681
IN O 16,892 1,149 8,746
IA V 4,491 13,502 −3,655
KS O 16,742 1,235 8,596
KY O 16,889 1,152 8,743
LA O 16,928 1,097 8,782
ME V 4,508 13,402 −3,638
MD V 4,543 13,407 −3,603
MA V 4,515 13,355 −3,631
MI W 4,113 13,806 −4,033
MN V 4,491 13,502 −3,655
MS O 16,834 1,214 8,688
MO O 16,769 1,208 8,623
MT V 4,491 13,502 −3,655
NE V 4,491 13,502 −3,655
NV V 4,479 13,409 −3,667
NH V 4,508 13,396 −3,638
NJ V 4,531 13,337 −3,615
NM O 16,809 1,074 8,663
NY V 4,522 13,642 −3,624
NC V 4,524 13,509 −3,622
ND V 4,491 13,502 −3,655
OH O 16,856 1,079 8,710
OK O 16,786 1,209 8,640
OR O 4,470 13,470 −3,676
PA V 4,523 13,374 −3,623
RI V 4,515 13,355 −3,631
SC V 4,520 13,459 −3,626
SD V 4,491 13,502 −3,655
TN V 4,538 13,507 −3,608
TX V 4,507 13,455 −3,639
UT V 4,475 13,471 −3,671
VT V 4,515 13,355 −3,631
VA V 4,502 13,402 −3,644
WA V 4,470 13,470 −3,676
WV V 4,523 13,374 −3,623
WI O 16,779 1,200 8,633
WY V 4,491 13,502 −3,655
US 8,146 10,382
Mean
*Plan name legend: B = Community Care Rx Basic; O = Humana
Prescription Drug Plans Complete; V = Advantage Freedom; W =
Prescription Blue Option 1.
†Lowest-cost plan in each state−mean lowest-cost plan for US overall.
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Patient Case 4: Osteoporosis, Hypertension,
and Chronic Pain
The mean estimated annual cost for the lowest-cost PDPs
across all states for this patient was $8,146 (Table 2). The
estimated costs of lowest-cost plans for this case varied more
widely around this mean than for the other cases, from $4,033
less (Michigan) to $9,034 more (Alaska). In addition, there was
more variation among the lowest-cost PDPs identified in each
state for this patient, with only 34 states having the most
common lowest-cost plan (Plan “V”) as the lowest-cost PDP.
The medication responsible for this substantial variation in
overall PDP cost was largely attributable to differences in price
for nasal calcitonin. On average, in each state the highest-cost
PDPs cost almost $10,400 more than the lowest-cost plans.
Affordability of Lowest-Cost PDPs
The lowest-cost PDPs for case 1 would, on average, consume
2.9% of the annual income for a beneficiary with COLA-MI in
each state (Table 3). Across the states, the share of COLA-MI
needed to pay for the lowest-cost PDPs for patient 1 ranged
from 2.2% to 10.6%. The correlation of estimated costs for the
lowest-cost PDPs with COLA-MI for case 1 was −0.34 (P=.01);
that is, in states with lower COLA-MI, the lowest-cost PDPs
were actually more expensive, not just in proportional terms
but in direct comparison. For example, COLA-MI is lower in
Mississippi ($20,602) than in Minnesota ($32,448) (Table 3),
but the estimated cost for the lowest-cost PDP is higher in
Mississippi than in Minnesota (Table 1).
The addition of insulin to the medical regimen (case 2)
increased the share of annual income to 6.4% on average,
ranging from 5.0% to 23.9% across the states. The correlation
of lowest-cost PDPs with COLA-MI was also negative (r=−.25)
but not statistically significant (P=.08).
For case 3, the affordability of the lowest-cost PDPs was 8.0%
of COLA-MI as a mean (range 6.0%–29.5%). The correlation of
lowest-cost PDPs with COLA-MI was −0.35 (P=.01).
For case 4, the mean lowest-cost PDP nationally would
consume 27.9% of the annual household income for the
COLA-MI beneficiary (range 12.9%–81.7%). There was no
significant correlation (r=.09) of the lowest-cost PDPs with
COLA-MI.
DISCUSSION
Interstate Variation in Expected PDP Costs
The Medicare Part D prescription drug benefit offers beneficia-
ries the promise of coverage for increasingly expensive medica-
tions, when many have lacked such coverage in the past.2
Overall, the implementation of this program has the potential
to improve the access of many beneficiaries to their prescrip-
tion medications.7–10,15 Although cost may not be the only
consideration for beneficiaries as they select their PDPs, high
prescription drug costs were a major motivation for the MMA7,8
and we expect that many beneficiaries heavily weigh the
anticipated cost of a PDP in their decision-making process.
Whether beneficiaries seek information online or via telephone
inquiries to CMS, their eventual source of information about
anticipated PDP costs is the same tool we used to derive the
measures in this study.
Our findings suggest a need for further Medicare Part D
program refinement to ensure nationwide balance in PDP
affordability. This is the first study to characterize state-to-
Table 3. Affordability of Lowest-Cost Medicare Prescription Drug
Plans in Each State, for Each Patient Case
State COLA-MI ($) Estimated proportion of COLA-MI for
zero-earner households to be spent on
lowest-cost PDP
Case 1 Case 2 Case 3 Case 4
AL 23,758 0.038 0.086 0.098 0.191
AK 24,555 0.042 0.083 0.127 0.700
AZ 33,818 0.023 0.051 0.067 0.140
AR 28,619 0.030 0.068 0.081 0.587
CA 20,491 0.039 0.087 0.108 0.218
CO 28,999 0.028 0.062 0.078 0.578
CT 28,848 0.029 0.068 0.079 0.165
DE 28,721 0.028 0.060 0.078 0.166
DC 7,595 0.106 0.239 0.295 0.639
FL 33,016 0.025 0.050 0.071 0.509
GA 20,390 0.047 0.100 0.122 0.221
HI 17,562 0.056 0.114 0.179 0.254
ID 33,100 0.024 0.055 0.067 0.135
IL 30,453 0.029 0.062 0.077 0.553
IN 28,805 0.030 0.064 0.084 0.586
IA 30,069 0.025 0.061 0.069 0.149
KS 36,420 0.023 0.051 0.062 0.460
KY 23,937 0.036 0.075 0.101 0.706
LA 23,272 0.040 0.082 0.105 0.727
ME 24,307 0.043 0.084 0.118 0.185
MD 25,515 0.032 0.071 0.088 0.178
MA 16,872 0.049 0.116 0.134 0.268
MI 31,569 0.029 0.063 0.074 0.130
MN 32,448 0.023 0.054 0.064 0.138
MS 20,602 0.042 0.091 0.114 0.817
MO 31,253 0.028 0.062 0.073 0.537
MT 30,006 0.025 0.059 0.069 0.150
NE 32,336 0.023 0.054 0.064 0.139
NV 20,900 0.047 0.096 0.105 0.214
NH 27,109 0.038 0.076 0.106 0.166
NJ 30,435 0.026 0.063 0.072 0.149
NM 21,475 0.040 0.087 0.108 0.783
NY 23,754 0.030 0.063 0.092 0.190
NC 23,197 0.040 0.089 0.103 0.195
ND 33,576 0.023 0.053 0.062 0.134
OH 29,944 0.030 0.063 0.079 0.563
OK 29,256 0.029 0.064 0.079 0.574
OR 31,670 0.026 0.062 0.070 0.141
PA 26,516 0.032 0.073 0.087 0.171
RI 26,979 0.031 0.071 0.084 0.167
SC 29,649 0.032 0.068 0.082 0.152
SD 30,618 0.025 0.060 0.068 0.147
TN 26,811 0.033 0.070 0.090 0.169
TX 20,530 0.041 0.089 0.113 0.220
UT 33,023 0.024 0.052 0.068 0.136
VT 27,152 0.030 0.070 0.084 0.166
VA 27,758 0.031 0.071 0.083 0.162
WA 28,336 0.029 0.069 0.078 0.158
WV 26,718 0.032 0.069 0.086 0.169
WI 29,548 0.029 0.063 0.078 0.568
WY 34,699 0.022 0.053 0.060 0.129
US Mean 29,228 0.029 0.064 0.080 0.279
Affordability is equal to the estimated annual cost of lowest-cost PDP in a
state for a given patient case divided by COLA-MI in that state.
COLA-MI cost-of-living-adjusted median income for zero-earner house-
holds, PDP prescription drug plan.
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state variation in expected PDP costs—ranging from hundreds
to thousands of dollars per person annually—for Medicare
beneficiaries with identical sets of prescriptions. Consider, for
example, two beneficiaries living in the neighboring states of
Florida and Georgia (different CMS regions), both of whom
resemble the patient in case 4 with regard to their chronic
conditions and prescription medications. For the lowest-cost
plan, the Florida resident will expect to pay $16,814, while the
Georgia resident will expect to pay $4,516. Despite higher
COLA-MI in Florida than in Georgia, Florida median-income
Medicare beneficiaries would expect to pay about 29% more of
their annual median income (in absolute terms) for this plan
than would Georgia Medicare beneficiaries.
Whether costs of the PDP on average consume as little as
3% of COLA-MI on average (case 1) or as much as 28% (case 4),
state-to-state variation in PDP affordability may have clinically
meaningful effects for Medicare beneficiaries. The greatest
concern, based on prior literature regarding seniors and their
medication use with regard to cost barriers,3–6 is that benefi-
ciaries in states with less affordable plans will cut back on
either their medications or their spending on essentials (food,
utilities) to make ends meet. In work by Heisler and collea-
gues,6 annual differences in pharmaceutical spending of
$300–$600 were associated with 4-fold-higher odds of reduc-
ing the purchase of necessities and a 2-fold-higher odds of
restricting their own medication use. A $300 difference is
smaller than the variation in least to most expensive lowest-
cost PDPs across states for all the patient cases we considered.
Therefore, PDP cost variation across states that we report may
be behaviorally and clinically meaningful.
State-to-state differences in PDP costs are certainly ex-
pected, based on prior literature regarding state and regional
differences in Medicare costs related to health care utiliza-
tion,11–13 and also based on stipulations in the MMA that PDPs
would act as independent bargaining units with pharmaceu-
tical manufacturers.7–9 Nevertheless, prior projections about
the impact of PDPs for beneficiaries8,10 and commentary about
the advantages and disadvantages of the MMA7 have not
previously centered on how the Part D benefit would differen-
tially affect otherwise similar beneficiaries in different states.
Nor have prior studies illustrated, as our analysis does, that
market forces for PDPs are generating circumstances in which
individuals in states with lower COLA-MI may, counterintui-
tively, expect to pay substantively higher proportions of their
income for the lowest-cost PDPs (cases 1 and 3), not just
because their incomes are lower but because the plans are
actually priced higher.
Our results indicate that market pressures within states
that may reduce drug plan costs do not, at this early phase of
the program, yield similar results across states. This finding is
similar to an analysis of plans in 5 states15 that found
between-state differences of less than $200 for beneficiaries,
based solely on their anticipated aggregate medication expen-
ditures. We believe that our between-state comparisons
revealed wider disparities because we explicitly considered
specific medications, the costs of which may vary considerably
across plans because of differences in formularies and dis-
counts with pharmaceutical houses.16
Variation in estimated affordability of PDPs across states
raises questions about how the lay public may perceive the
equity of this federal program. Between-state variations in PDP
affordability may prompt future calls for a restructuring of Part
D to allow for Medicare to negotiate with pharmaceutical
manufacturers as a single entity, as is the case for the Veterans
Administration. Some analysts have asserted that single-entity
bargaining would not be as effective in lowering prices as PDP-
level bargaining.9 On the other hand, a recent single-market
comparison of Medicare prescription discount programs (pre-
decessors of PDPs) found that savings in drug costs through
market competition were smaller than savings from the
Veterans Administration acting as a large purchaser.20
Intrastate Variation in Expected PDP Costs
Another key finding in this analysis is the considerable in-
rastate variation in expected PDP costs for all 4 case scenarios.
The difference between the expected annual costs of the
lowest- and highest-cost PDPs may be considered a financial
risk for incompletely informed beneficiaries. The size of this
risk was about $1,500 on average for the least expensive case
scenario (case 1), and exceeded $10,000 on average for the
most expensive combination of medications (case 4).
The variable size of this risk illustrates the critical impor-
tance for Medicare beneficiaries of using available tools and
resources to select the PDP that will best suit them. While the
online tool provided by CMS appears easy to use, a recent
national study revealed that less than one-third of seniors
have ever gone online.21 Although assistance via telephone and
other avenues are available for Medicare beneficiaries, lay
press reports indicated that agencies have struggled to meet
the demand from beneficiaries for information tailored to their
medical needs and combinations of prescription medica-
tions.22,23 These challenges, however, may be ameliorated in
the future because of cumulative experience of CMS staff in
managing Part D, and because the key transition period for
Part D in 2005–2006 involving the enrollment of >30 million
Medicare beneficiaries is now past.9
Study Limitations
Our findings must be interpreted with some caveats inherent
to the study design. We considered 4 case scenarios based on
actual patients, but in so doing limited our findings only to
standardized patients and could not incorporate potentially
meaningful variations in clinical care strategies (e.g., broader
use of generic substitution) that might have affected our find-
ings regarding variation in PDP costs within or across states.
In addition, because we considered patients’ lists of medica-
tions but did not have information about costs incurred by
these patients in the pre-MMA era, we could not assess state-to-
state variations in costs in both the pre-MMA and MMA eras. It
is possible that the interstate variation we observe regarding
lowest-cost PDPs is similar to variations in costs borne by
beneficiaries living in different states in the pre-MMA era.
Another study limitation, inherent to the implementation of
PDPs, is that costs can change at any time as a result of
renegotiated prices between PDPs and pharmaceutical manu-
facturers (e.g., related to the approval of new generic formula-
tions) within a given plan year. We did not explicitly include
this scenario in our analysis; future studies of Medicare
beneficiaries’ experiences with PDPs will provide the opportu-
nity to examine this aspect of uncertainty in the program. To
the extent that plan costs change, the relative affordability of
plans across states will change accordingly.
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Conclusions
The affordability of Part D PDPs varies for Medicare beneficia-
ries living in different states, in some instances quite markedly,
for reasons that are likely attributable to the market-based
principles of the MMA. In addition, intrastate variation in
expected plan costs presents possible financial risks to
beneficiaries as they choose their PDPs.
Variations in plan affordability may affect Medicare benefi-
ciaries’ use of medications under the MMA. Although some
variation in plan costs may be expected based on market
differences, the extent to which PDP affordability varies across
states may influence the success of Part D as a major reform of
the Medicare program.
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